• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, tolerability and Pharmacokinetics of oral AZD2423 after Single Ascending Doses in Healthy Male and Female Volunteers without Childbearing Potentiall

Disease
analgaesia
Drug Name
AZD2423
Generic Name
AZD2423
Sponsor
AstraZeneca
Drug Status
In Development
Phase
I
Start Date
Jan 18, 1971
Study Name
D2600C00001
Study Id
D2600C00001
ClinicalTrials.gov ID
NCT00940212
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013